Neil Barr
Lawyers
Filters
Josh Harris acquisition of Washington Commanders
We are advising the partnership led by Josh Harris on the transaction
Sterling Equities sale of the New York Mets
We advised Sterling Equities on the sale
McKesson splits off interest in Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offer by McKesson to exchange shares of McKesson common stock for shares of PF2 SpinCo, Inc. (“SpinCo”) common stock owned by…
Brink's $860 million acquisition of the majority of the cash operations of G4S
Davis Polk is advising The Brink’s Company as special tax counsel on its agreement to purchase for approximately $860 million (£660 million) the majority of the cash operations of G4S plc…
Morgan Stanley $13 billion acquisition of E*TRADE Financial
Davis Polk is advising Morgan Stanley on its $13 billion acquisition of E*TRADE Financial Corporation. The transaction is expected to close in the fourth quarter of 2020, subject to…
Victoria’s Secret separation from L Brands in a transaction with Sycamore
We are advising L Brands on the separation of Victoria’s Secret
Davis Polk Advises Masco Corporation on the Sale of Milgard Windows to MI Windows and Doors
Davis Polk is advising Masco Corporation on the approximately $725 million sale of Milgard Manufacturing Incorporated, a manufacturer of windows and patio doors, to MI Windows and Doors…
Tax counsel to Danaher on the separation and IPO of its dental business
Davis Polk is acting as special tax counsel to Danaher Corporation on the separation of its dental division into a new publicly traded company called Envista Holdings Corporation and the …
Westinghouse Air Brake Technologies Corporation $1.5 Billion Secondary Offering
Davis Polk advised General Electric Company in connection with the SEC-registered secondary offering of 20,485,156 shares of common stock of Westinghouse Air Brake Technologies Corporation …
Tax counsel to Pfizer on the combination of its Upjohn business with Mylan
Davis Polk is acting as special tax counsel to Pfizer Inc. on the combination of its off-patent branded and generic established medicines business, Upjohn, with Mylan N.V. Under the terms…